Background Observational evidence suggests that community-based services for people with schizophrenia can be successfully provided by community health workers, when supervised by specialists, in low-income and middleincome countries. We did the COmmunity care for People with Schizophrenia in India (COPSI) trial to compare the eff ectiveness of a collaborative community-based care intervention with standard facility-based care.
Introduction
The absence of accessible services for people with schizophrenia in low-income and middle-income countries contributes to the substantial public health burden of schizophrenia; poor health and social outcomes, including poverty; 1 social exclusion attributable to stigma and discrimination; and human rights violations in these settings. 2 In many high-income countries, clinical and social services for people with schizophrenia are coordinated by specialist communitybased multidisciplinary teams. However, such specialist services are not presently feasible in low-income and middle-income countries because of serious human and fi nancial resource constraints. Hence, development of alternative methods for provision of accessible, community-based services for people with schizophrenia within these countries is a global public health priority. 3 Increasing observational evidence from low-income and middle-income countries shows that the communitybased rehabilitation method of services, delivered through community health workers working with mental health specialists, might be a feasible way to deliver services that improve clinical and social outcomes of people with schizophrenia. 4 However, such evidence from randomised controlled trials in these settings is scarce.
We did the COmmunity care for People with Schizophrenia in India (COPSI) study to compare the clinical eff ectiveness of two service delivery methods for people with schizophrenia and their caregivers. We postulated that a combination of facility-based care and collaborative community-based care would be more eff ective than facility-based care alone for people with moderate to severe schizophrenia for changes in symptoms and disabilities.
Methods

Study design and patients
A description of the study design, methods, and analysis plan has been published elsewhere. 5 We undertook this multicentre, parallel-group, randomised controlled trial between Jan 1, 2009 and Dec 31, 2010, at three sites in India (four subdistricts of Kancheepuram district, Tamil Nadu; Goa; and Satara District in Maharashtra). The Tamil Nadu site was rural with no locally accessible mental health services; Satara and Goa had a mixed urban and rural population with easier access to specialist care in public and private facilities.
Because COPSI was designed as a pragmatic randomised trial, we used broad inclusion criteria. Eligible patients aged 16-60 years had a primary diagnosis of schizophrenia according to the tenth edition of the International Classifi cation of Diseases, Diagnostic Criteria for Research (ICD-10-DCR); an illness duration of at least 12 months of at least moderate severity overall, as rated by the clinical global impression-schizophrenia scale; 6 and intended to reside in the study regions for 12 months. In Tamil Nadu, a two-staged, key-informant community survey was done to identify participants who met inclusion criteria, whereas in Goa and Satara, participants were recruited from the clinical practices of the collaborating psychiatrists. Thus, we used two pathways for recruitment: (1) people with schizophrenia from within the existing caseloads, and (2) people with schizophrenia who presented for care at treatment facilities for the fi rst time. Across the study sites, collaborating psychiatrists screened people with a primary ICD-10-DCR diagnosis of schizophrenia for eligibility. For each participant, one primary caregiver was identifi ed and asked for consent to participate. All eligible participants were provided with an overview of the study in the relevant local language before seeking informed consent (appendix).
The COPSI-informed consent procedure was undertaken by a team of trained interviewers using a fl ipchart to enable people who were not literate to understand the implications and risks of participation. We enrolled participants and caregivers if both provided written or independently witnessed (for people who were not literate) informed consent. Ethics approval was obtained from the institutional review boards of Sangath and SCARF, and from King's College London and the London School of Hygiene & Tropical Medicine. The trial monitoring committee provided additional oversight of the trial.
Randomisation and masking
Patients were randomly assigned in a 2:1 ratio, via computer-generated randomisation list with block sizes of three, six, or nine, to receive either collaborative community-based care plus facility-based care or facilitybased care alone. Randomisation was stratifi ed by study site. For each site, the randomisation list was generated independently by the trial statistician and transferred to the site data manager before recruitment. The data manager had no role in the recruiting of participants and held the passwords for the randomisation lists; individuals recruiting participants did not have access to the randomisation lists or the passwords.
Outcome assessors were masked to group allocation. Because neither participants nor the family caregivers were masked to their allocation status at the 6 month and 12 month interviews, unmasking was possible during the outcome assessments. To minimise this possibility, we kept the research and intervention teams physically separate during the trial, asked participants and caregivers fi rst at the time of assessments to not disclose whether they had received home visits from the community health worker, and the primary outcome measures (positive and negative syndrome scale [PANSS] and the Indian disability evaluation assessment scale [IDEAS]) were completed fi rst. Instances of unmasking were recorded by the researchers. If unmasking happened at the time of the 6 month assessment, a separate researcher undertook the 12 month assessments. Facility-based care was available to participants in both study groups; thus, treating psychiatrists were aware of the allocation status of participants.
Procedures
The collaborative community-based care intervention was motivated by our experience with development of a similar intervention in a rural resource-poor setting in India. 4 This intervention was further refi ned in iterative formative phases as recommended by guidelines from the Medical Research Council for development and assessment of complex interventions. Initially, we selected components of the intervention from a systematic review of the scientifi c literature. To help match the concerns of people with schizophrenia and their caregivers with the intervention components, we additionally identifi ed outcomes that mattered to these individuals. We undertook further pilot work to address operational challenges in delivery of the interventions. This process identifi ed challenges in delivery of the home-based sessions, organisation of the supervision for community health workers as planned, and the need for a simpler set of information materials. This identifi cation led to adaptations such as specifi c strategies to address planning for the home-based sessions, the risk of attrition, and the development of material such as the fl ipchart element of the manual to help community health workers communicate the contents of the psychoeducation sessions. The collaborative community-based care intervention was designed to promote collaboration between the person with schizophrenia, their caregivers, and the treatment team to deliver a fl exible, individualised, and needs-based intervention. 7 The intervention was delivered by community health workers who had at least 10 years of schooling and good interpersonal skills. These workers were systematically trained over 6 weeks and assessed for competence with the intervention manual.
To meet the prespecifi ed quality assurance and fi delity standards, community health workers at each site were supervised by intervention coordinators. Coordinators were psychiatric social workers trained in the necessary supervision and monitoring skills. The treating psychiatrists supervised the intervention delivery through quarterly team reviews and ongoing supervision of community health workers. Continued education and training of the health workers was an essential part of the intervention. Panel 1 describes components of the collaborative community-based care intervention. To standardise the intervention across sites, the COPSI study team developed a manual to be used fl exibly according to the individual needs of participants. The intervention was delivered in three phases: (1) the intensive engagement phase (0-3 months), including six to eight home visits made by community health workers; (2) the stabilisation phase (4-7 months), with sessions delivered once every 15 days; and (3) the maintenance phase (8-12 months), with sessions delivered once a month.
The control group received the facility-based care indication to show the crucial diff erences compared with collaborative community-based and facility-based careie, the location of services and the use of community health workers. Facility-based care represents the usual care provided by specialist mental health practitioners for people with schizophrenia and their families in India. The operational aspects of the facilities diff ered across trial sites. In Goa there were four private clinics, supported by inpatient facilities. In Satara, the four private psychiatrists operated as a group practice from one facility and shared an inpatient service. In Tamil Nadu, care was from a clinical team consisting of psychiatrists and assistants at a designated facility some distance away from most patients; this service is similar to those in many rural areas in India.
Although the sites varied somewhat, the content of the control-based care provided was similar. Briefl y, the intervention was delivered by the psychiatrists through consultations, lasted 10-15 min, and all people with schizophrenia were prescribed antipsychotic drugs.
Psychiatrists also provided information about the illness, encouraged adherence to drugs, and discussed specifi c concerns raised.
Outcomes
The primary outcome was a change in symptoms and disabilities in 12 months. Secondary outcomes were adherence to antipsychotic treatment and experiences of stigma and discrimination. For caregivers of people with 20 lost to follow-up 10 refused 8 were not found or had moved 2 had died schizophrenia, the secondary outcomes were changes in knowledge and attitudes about the illness, changes in felt burden of caring, and experiences of stigma and discrimination. Additionally, we included an analysis of health economics with an assessment of the costs and cost-eff ectiveness of the collaborative community-based care and facility-based care intervention compared with facility-based care alone.
Symptoms were measured at baseline and 12 months with the PANSS, 8 which has been previously used in India. PANSS comprises 30 items measuring positive and negative symptoms and general psychopathology. To assess disability, we used the IDEAS at baseline, 6, and 12 months. IDEAS has been validated in India 9 and measures self-care, interpersonal activities, communication and understanding, and work. 10 The trial protocol has full details of the measures used for the secondary outcomes. 5 In brief, we used the following scales: a 5-point ordinal scale developed for the study (adherence); discrimination and stigma scale, 11 the alienation subscale of the internalised stigma of mental illness scale, 12 and an item on willingness to disclose the illness (stigma and discrimination of participants); the knowledge about schizophrenia interview scale 13 (caregiver knowledge and attitudes); the burden assessment schedule (family burden of caring); 14 the relevant section of the family interview schedule; 15 and a modifi ed version of the item on willingness to disclose the illness (caregiver experiences of stigma and discrimination); and cost of illness schedule (health economic outcomes).
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Statistical analysis
On the basis of data from the only relevant study in India, 17 we assumed that an absolute diff erence of a 20% reduction in mean PANSS total score, from 65 to 52 (SD 10), would be highly clinically signifi cant. The intraclass correlation between sites in the facility-based care group was estimated as 0·05; for the intervention group (which also includes between-community health worker clustering), this correlation was assumed to be 0·1. These estimates were conservative on the basis of a review of primary care variables. 18 An allocation ratio of 2:1 was used to allow for the between-health worker clustering eff ect in the intervention group. 19 The estimated required total sample size of 241 was increased to 282 to allow for 15% attrition during the study. With α=0·05, this sample size had 80% power to detect an eff ect size of 0·8 (diff erence in PANSS score of 7·2 units [SD 9]), and 90% power to detect an eff ect size of 1 (diff erence in PANSS score of 9 units [9] ). We obtained data for IDEAS and adherence with palmtop computers, whereas PANSS data were obtained with pen and paper. Analyses followed the prespecifi ed data analysis plan and no interim analyses were done. All analyses used Stata version 11.2.
We analysed descriptive summaries of sociodemographic and clinical data for all participants at baseline, and for outcome measures at baseline, and at 6 month and 12 month follow-up points, and compared them by group. PANSS and IDEAS scores used were total score, domain sub-scores, and proportion of patients improving by more than 20% from baseline. For PANSS, a value of 30 was fi rst subtracted from the proportion of patients improving by more than 20% from baseline because this is the minimum total score. We used histograms of data for the control group to assess normality of the distribution of the data and to identify outliers.
For inferential analysis, participants were analysed by original randomised group (a modifi ed intention-to-treat approach). We used linear mixed-eff ect regression to analyse the intervention eff ect on continuous outcomes (the 12 month PANSS and IDEAS total scores), adjusted for baseline scores and site as fi xed terms, and a random eff ect to allow for community health workers clustering in the intervention group. We used mixed-eff ects logistic regression to analyse the intervention eff ect on binary outcomes, and mixed-eff ects ordinal logistic regression for ordered categorical outcomes. For the IDEAS score, we did a longitudinal analysis, including both 6 month and 12 month outcomes, using a random-eff ects model including a time × treatment term allowing for intervention eff ect changes over time. The eff ect of adherence was assessed by categorisation of self-reported adherence at 12 months as complete or most of the time, and including an interaction term between adherence and intervention group. No imputation was made because missing data were fewer than the predefi ned threshold specifi ed in the trial protocol.
Costs were reported in Indian Rupees (INR) and also International Dollars (I$) with an exchange rate of INR 19·13 to I$1. Total costs were compared and bootstrapped CIs computed. We calculated incremental costeff ectiveness ratios to show the extra cost for collaborative community-based care and facility-based care to achieve an extra unit improvement in the primary outcomes.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
The fi gure shows the trial profi le. 187 eligible patients were randomised to the collaborative community-based care and facility-based care group (70 in Tamil Nadu, 60 in Goa, and 57 at Satara) and 95 were randomised to the facilitybased care group (35 in Tamil Nadu, 32 in Goa, and 28 at Satara We monitored the intervention for fi delity and quality assurance purposes by collecting key process indicators for both groups. The mean number of sessions with community health workers that were received by participants in the community-based care and facilitybased care group was 17·97 (SD 7·12, 95% CI 16·94-19·00), and 169 (90%) received the predefi ned minimally eff ective 12 sessions. The mean number of contacts with a treating psychiatrist was ten (95% CI 9·53-10·89) in the intervention group and eight (6·98-9·11) in the control group. At 12 months, we noted a reduction in overall symptoms in both groups (table 2). Total PANSS score was lower at 12 months in patients in the intervention group than in those in the control group, after adjustment for baseline PANSS scores and site (table 2) . However, no diff erence was shown in the proportion of participants who had a reduction of more than 20% in overall symptoms (85 [51%] vs 44 [51%]; p=0·89).
The eff ect was stronger for overall disability ( disability scores at 12 months than at 6 months, after adjustment for baseline score and site (p=0·01; appendix). The appendix shows the association of complete or almost complete adherence between the treatment groups. At 12 months, 153 (61%) participants reported complete adherence to drugs, and a further 57 (23%) reported adherence most of the time. At both 6 months and 12 months, participants in the intervention group were signifi cantly more likely to report adherence all or most of the time to prescribed drugs compared with those in the control group (appendix). We noted a similar eff ect on adherence reported by caregivers at 12 months (appendix).
The study had low power to detect intervention eff ects by level of adherence, but there was a trend towards reduced symptoms in patients who had good adherence to drugs (PANSS adjusted mean diff erence -3·85 [SE 6·94] in patients with good adherence vs −0·52 [5·13] in those with poor adherence; p value for eff ect modifi cation between adherence and treatment group=0·56). For IDEAS, we noted a similar, but smaller, trend of greater improvement in patients with good adherence compared with those with poor adherence (-1·14 [SE 1·33] vs 0·09 [0·90]; p value for eff ect modifi cation=0·21).
Participants in the intervention group did not report lower stigma than did those in the control group (adjusted OR for any reported alienation 1·15, 95% CI 0·66-2·02; table 4). Moreover, participants in the intervention group were more likely to be unwilling to disclose their illness at 12 months than were those in the control group (table 4) . However, we noted clinically and statistically signifi cant reductions in reported experiences of stigma and discrimination from baseline to 12 months in both groups for three of the four outcome measureseg, the proportion of participants reporting any negative discrimination (p=0·004; table 4).
We noted no evidence of an intervention eff ect on mean total score on the knowledge about schizophrenia interview scale (adjusted mean diff erence 0·34, 95% CI −0·28 to 0·96), or on burden (−0·04, −0·18 to 0·11), reported stigma (1·35, 0·72-2·53), or willingness to disclose their family members' illness (1·43, 0·80-2·53).
The mean number of sessions in the intervention group was 17·1 (6·9) with slight variation between sites (appendix). Travel times were highest in Tamil Nadu (appendix). Costs of input from the community health workers were exceeded by the costs of supervision (appendix). Total intervention costs were highest in Goa and lowest in Satara (appendix). Other service costs varied between sites with the highest for participants in in the intervention group in Goa (appendix). Total costs in the 12 months of follow-up were highest for participants in the intervention group, mainly because of staff supervision costs (appendix). The mean diff erence between the two groups adjusted for baseline was INR 9427 (95% CI 6584-12 224), which is equivalent to I$493 (344-639). The incremental cost-eff ectiveness ratio (ICER), based on the PANSS, is defi ned as the incremental cost of community-based care and facilitybased care group compared with facility-based care alone (INR 9427) divided by the incremental reduction in symptoms (3·75). This ratio shows that a cost of INR 2514 (I$131) is needed to achieve a 1 point reduction on the PANSS. The ICER based on the IDEAS is INR 9365 divided by 0·95-ie, INR9923 (I$519) to achieve a 1 point reduction on the IDEAS (appendix).
Four patients died during the study. Two (50%) of these deaths were because of suicide (one in each treatment group), whereas the other two (50%) were due to complications of a road traffi c accident and pre-existing cardiac disease. 18 (73%) patients were admitted to hospital during the course of the trial; of these, 17 were in the intervention group. Seven (39%) of these admissions were related to physical health problems, such as acute IDEAS=Indian disability evaluation assessment scale. *Linear regression including a random eff ect for community health-care worker and covariance for baseline score and site. †p=0·04. ‡Ordinal logistic regression fi tted with Generalized Linear Latent and Mixed Models (GLLAMM). Model includes a random eff ect for community health-care worker and covariance for baseline score and site. §p=0·001. 
Discussion
Our fi ndings show that the collaborative communitybased intervention including supervised community health workers was more eff ective than were facilitybased services for people with moderate to severe schizophrenia. The overall benefi ts of community-based plus facility-based care were modest at 12 months and were most evident in the reducing of disabilities associated with schizophrenia and in promotion of adherence with prescribed drugs. Additionally, we noted an overall trend for improvement in the severity of symptoms with the intervention; however, across the whole study, this trend was not statistically or clinically signifi cantly diff erent in comparison to facility-based care at 12 months. We have described the association of PANSS score with the intervention (p=0·08) as modestly more eff ective, which is in line with recommendations about this issue. 21 In view of this fi nding, we focused on the eff ect size and 95% CI whilst showing p values, which is in line with CONSORT 2010 guidelines for reporting of fi ndings from clinical trials. 22 This symptom-related fi nding is better than those from previous research about community mental health interventions in high-income countries, for which most studies tend to report improvements in service satisfaction, quality of life, and aspects of disability, but do not show symptom changes. 23 Because the study intervention included components that were designed to improve self-care, structuring activities, social interactions, and work ability, the greater eff ectiveness of the intervention in reducing disability, compared with facilitybased care alone, is understandable.
The stigma-related fi ndings are consistent with the explanation that facility-based care alone is eff ective in reducing stigma and discrimination, and that there is little additional contribution from community-based care. The community-based plus facility-based care intervention did not produce any additional changes in caregivers understanding and knowledge of schizophrenia. This fi nding is surprising and needs further exploration, especially from the available qualitative data available from a subset of participants. The absence of an association between caregivers' burden and the greater reduction of disability levels in participants in the intervention group than in those in the control group is also unexpected. This fi nding could show that an increased quantum of improvement in disability scores is needed to translate this improvement into matching improvement in caregiver burden.
The health economic fi ndings showed that costs in the intervention group were on average greater than those in the control group, and that about a third of these additional costs were attributable to supervision.
Eff ective staff supervision is increasingly seen as a cornerstone for interventions including community health workers that are sustainable in the long term, and is fundamental to the delivery of WHO's mhGAP Intervention Guide. The average greater cost for participants in the intervention group over the study period was almost INR 9500 (roughly I$500); therefore, a judgment should be taken as to the value in terms of the clinical and social improvements identifi ed for a group of highly vulnerable people.
Recent randomised trials from low-income and middleincome countries have reported the benefi ts of family psychoeducation and adherence management in improvement of outcomes in people with schizophrenia. [24] [25] [26] [27] In all these trials, participants were recruited from hospital settings and the interventions were provided by specialists. By contrast, in our COPSI trial, supervised community health workers delivered the psychosocial intervention in the community. The fi ndings of improved disability and adherence with additional psychosocial interventions are common across COPSI and these other studies.
Although the overall eff ects of community-based plus facility-based care are moderate in scale, the primary outcomes diff er greatly when disaggregated by site. This diff erence is probably because of the methods of recruitment and the consequent characteristics of the participants. At both Satara and Goa, facility-based care was provided by psychiatrists in well-established clinics and participants were therefore recruited from an existing pool of people with schizophrenia who were already receiving ongoing high-quality treatment. This ongoing usual care included many elements of community-based and facility-based care, albeit unstructured. In this context, community-based and facility-based care might have added little to the cumulative eff ects of the facilitybased care and did not provide substantial additional benefi ts. However, in Tamil Nadu, participants were recruited from a population-based sample and the additional community-based care intervention did provide substantial benefi ts.
Were specifi c, evidence-based interventions actually delivered to the intervention group? We ensured this delivery by fi rst, following an independent assessment procedure for individualised clinical and social needs (using Camberwell assessment of needs). The team also adapted the manual to deliver the intervention according to the needs identifi ed by each participant. Because these interventions were intensively supervised, we are reasonably confi dent that community-based and facilitybased care delivered more than generic support from the community support worker and did in fact deliver interventions matched to individual needs.
Were all participants at least moderately severely disabled as specifi ed in the study protocol? To ensure that fi rst-contact patients did meet this criterion, details were collected by an experienced senior member of the clinical team. The psychiatrist then reviewed the information and did a detailed clinical assessment to decide if each participant fulfi lled the criteria for ICD-10 schizophrenia, and if they met the severity threshold by using criteria from the clinical global impression-schizophrenia scale for ICD-10 schizophrenia. Indeed, our trial was designed to include people with schizophrenia with a high overall severity for whom additional, community-based care would be justifi able in the context of scarce resources. Thus, participants in the trial had a median duration of about 7 years of the illness, at least a moderate severity of symptoms and disabilities, and high levels of social adversity. For this group of people with long-term and severely disabling symptoms and various social problems, these modest improvements in disability and symptoms could be viewed as important outcomes. Indeed, it was striking that the outcome that improved the most disability matched the outcome that mattered the most to participants.
Clinical improvement in people with severe schizophrenia is often a gradual process and the fairly short duration of follow-up is a limitation of our trial. The longitudinal analysis of the disability data shows that signifi cant improvements from the intervention happened between the 6 month and 12 month period, suggesting that a longer duration of follow-up is needed to show the additional benefi ts of the psychosocial intervention. 4 These fi ndings are important because they suggest the potential use and limitations of the community-based and facility-based care intervention. With extrapolation from the fi ndings in Tamil Nadu, and in view of the modest overall eff ectiveness and the additional costs involved, community-based and facility-based care might be best deployed in a defi ned catchment-areabased population as an initial strategy of making care more accessible and equitable (by circumvention of barriers to treatment). Furthermore, the communitybased care intervention is clearly of restricted use in situations when the high-quality facility-based care is provided to a stable group of people with schizophrenia who are well engaged with their psychiatrists. The results also suggest that for people with moderate to severe schizophrenia, the interventions should focus on social and economic recovery and on changing the environmental barriers to care.
In the global mental health context, the results strengthen the case for consideration of the adoption of community-based plus facility-based care as an initial step in the provision of services to where they are needed and scarce (as is the case in many low-income and middle-income countries); this provision might need to be progressively supplemented by intensive or specialist services for patients who are diffi cult to treat, as is common in high-income countries. 28 In our trial, community health workers were trained for 6 weeks because the requirements of working in the context of a highly structured randomised trial are somewhat more
Panel 2: Research in context
Systematic review Several systematic reviews have been done to assess the evidence base for community services for people with schizophrenia in low-income and middle-income countries. 30 Except for some randomised trials of psychoeducational interventions from China, few trials from other low-income and middle-income countries have assessed community services rigorously. However, some recent randomised trials have tested the eff ectiveness of psycho-educational interventions and adherence management strategies for people with schizophrenia and their caregivers from other low-income and middle-income countries. [24] [25] [26] [27] The results show that both psychoeducation and adherence management are eff ective across a range of outcomes. However, there is an over-representation of studies done in specialist hospital settings and in settings where the interventions were delivered by specialist mental health workers, making generalisation of the results to community settings uncertain. As yet, no randomised trials are available of a community-based, multicomponent intervention delivered by community health workers from low-income and middle-income settings.
Interpretation
The community-based care intervention provided collaboratively by a team consisting of community health workers was more eff ective for people with moderate to severe schizophrenia for reducing disability and improving adherence compared with usual, specialist care delivered from treatment facilities. Our fi ndings provide rigorous evidence about the eff ectiveness of use of supervised community health workers in provision of accessible, community-based services to people with schizophrenia-a strategy that has been advocated as a pragmatic method to scale up service coverage when specialist resources are scarce in low-income and middle-income countries.
complicated than in real-life health programmes, whereas a briefer initial training programme of 3 weeks is likely to be more sustainable.
These fi ndings have both strong internal validity and are potentially generalisable. The large sample size, the successful masking of allocation, the endpoint outcome data collected with fairly low rates of unmasking, the delivery of community-based plus facility-based care according to protocol across the sites, and the low attrition rates, add to the internal validity of the fi ndings. The broad inclusion criteria and the fact that participants with a need for additional community care were recruited from real-world clinical settings across three diverse sites and practice arrangements in India all suggest that the fi ndings of the trial are generalisable to similar settings in other low-income and middle-income countries.
These results add to the evidence base for the use of community health workers in the enhancement of access to services for people with schizophrenia in low-income and middle-income countries where specialist resources are few (panel 2). WHO and the Expert Policy Group of the Ministry of health in India have recommended use of non-specialist health workers to deliver communitybased psychosocial interventions to scale up services in low-income and middle-income countries. 29 . Within this global and national context, our fi ndings are an important addition to the ongoing policy and advocacy eff orts to make evidence-based services available for many more people with schizophrenia in low-income and middle income countries in the near future.
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